IGC Pharma, Inc.|4Jun 28, 9:25 PM ET

GRIMALDI CLAUDIA 4

4 · IGC Pharma, Inc. · Filed Jun 28, 2023

Form 4

Period: 2023-03-31

Director

Transactions

Exercise/Conversion
Common Stock
2023-03-31+58,334→ 700,488 total
Exercise/Conversion
Restricted Stock Units
2023-03-31−83,333→ 83,833 total
→ Common Stock (83,333 underlying)
Exercise/Conversion
Common Stock
2023-03-31+83,333→ 642,154 total
Award
Restricted Stock Units
2022-05-25+175,000→ 175,000 total
→ Common Stock (175,000 underlying)
Award
Restricted Stock Units
2023-06-20+300,000→ 300,000 total
→ Common Stock (300,000 underlying)
Exercise/Conversion
Restricted Stock Units
2023-03-31−58,334→ 116,666 total
→ Common Stock (58,334 underlying)
Award
Restricted Stock Units
2023-06-20+380,000→ 380,000 total
Exp: 2033-03-31→ Common Stock (380,000 underlying)

Footnotes (5)

[F1]On July 19, 2021, the Reporting Person was granted RSUs equally vesting over three years starting March 2022.
[F2]On May 25, 2022, the Reporting Person was granted RSUs subject to vesting equally over three years starting on March 31, 2023.
[F3]On June 20, 2023, the Reporting Person was granted RSUs subject to vesting equally over three years starting on March 31, 2024.
[F4]On June 20, 2023, the Reporting Person was granted RSUs subject to vesting according to specific milestones set by the Company's Board of Directors. The RSUs vest when milestones are achieved.
[F5]Each restricted stock unit represents a right to receive one share of IGC common stock.

Documents

1 file